At the time of writing, MoonLake Immunotherapeutics [MLTX] stock is trading at $39.65, up 2.53%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MLTX shares have gain 5.06% over the last week, with a monthly amount drifted -8.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on March 18, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $67. Previously, Goldman upgraded its rating to Buy on January 17, 2025, and elevated its price target to $82. Wolfe Research downgraded its rating to a Peer Perform. Oppenheimer initiated its recommendation with a Outperform and recommended $104 as its price target on June 25, 2024. Goldman started tracking with a Neutral rating for this stock on April 02, 2024, and assigned it a price target of $62. In a note dated February 15, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $77 on this stock.
For the past year, the stock price of MoonLake Immunotherapeutics fluctuated between $36.52 and $58.26. Currently, Wall Street analysts expect the stock to reach $67 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $39.65 at the most recent close of the market. An investor can expect a potential return of 68.98% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.60 points at the first support level, and at 37.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.84, and for the 2nd resistance point, it is at 42.03.
Ratios To Look Out For
It is important to note that MoonLake Immunotherapeutics [NASDAQ:MLTX] has a current ratio of 21.11. Also, the Quick Ratio is 21.11, while the Cash Ratio stands at 0.01.
Transactions by insiders
Recent insider trading involved BVF PARTNERS L P/IL, Director, that happened on Oct 04 ’24 when 2.0 million shares were sold. Director, Sturge Simon completed a deal on Oct 04 ’24 to sell 0.17 million shares.
